Identification and characterization of a putative new psychoactive substance, 2-(2-(4-chlorophenyl)acetamido)-3-methylbutanamide, in Spain
Identification and characterization of a putative new psychoactive substance, 2-(2-(4-chlorophenyl)acetamido)-3-methylbutanamide, in Spain
复制标题
DOI:
10.1002/dta.2182
复制
发表时间:
2017-07-01
影响因子:
2.9
通讯作者:
Ibanez, M.
中科院分区:
文献类型:
--
作者:
Fabregat-Safont, D.;Fornis, I.;Ibanez, M.
The term ‘new psychoactive substances’(NPS) refers to synthetically changed natural compounds or newly designed compounds intended to elicit a psychotropic response such as stimulation, hallucination or sedation.[1] According to the European Monitoring Centre for Drugs and Drug Addiction of the European Union, more than 560 NPS are currently being monitored, and 98 of these substance were reported for the first time in 2015.[2, 3] Despite that, there are still many NPS that are not being monitored, and therefore their health effects are not yet studied. Hence, many cases of intoxication and death related to NPS have been reported in the past few years, highlighting the public health risks of these substances.[4] One of the challenges of monitoring NPS is the continuous structural evolution to evade regulation, so when one substance is banned or controlled, several new compounds replace it in the market.NPS are usually found with various appearances, like incenses, bath salts, herbal blends or party pills, sold through an unregulated market, different websites or smart-shops.[4, 5] These products are typically known as ‘legal highs’. Synthetic cannabinoids, synthetic cathinones and amphetamines constitute the largest groups of NPS, although opioids, tryptamines, benzodiazepines, piperazines and phenethylamines are also common.[2, 3] Synthetic cathinones and amphetamines are sold as replacements for stimulants, and have been reported in pills, crystal and sniff powder.[6] Synthetic cannabinoids are commonly sold as herbal blends or spices, replacing cannabis.[7]